Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
IDEAYA Biosciences ( (IDYA) ) has shared an announcement.
On May 5, 2026, IDEAYA Biosciences filed a new automatic shelf registration statement on Form S-3ASR with the SEC to replace its prior shelf registration that was set to expire on June 26, 2026, effectively terminating the older registration under applicable securities rules. The company also filed a prospectus supplement the same day tied to its existing Open Market Sales Agreement with Jefferies, preserving the ability to issue up to approximately $156.6 million of additional common stock under its at-the-market program, which maintains financial flexibility to raise equity capital as needed.
As of the termination of the prior registration, IDEAYA had already sold about $193.4 million of common stock under the sales agreement, leaving roughly $156.6 million in remaining capacity that is now covered by the new shelf registration and related prospectus supplement. Legal counsel Latham & Watkins issued an opinion dated May 5, 2026, confirming the validity of the shares that may be sold under this structure, underscoring that these filings support the company’s continued access to public equity markets while adhering to securities law requirements.
The most recent analyst rating on (IDYA) stock is a Buy with a $62.00 price target. To see the full list of analyst forecasts on IDEAYA Biosciences stock, see the IDYA Stock Forecast page.
Spark’s Take on IDYA Stock
According to Spark, TipRanks’ AI Analyst, IDYA is a Neutral.
The score is driven primarily by strong balance-sheet positioning but offset by persistent losses and historically weak cash flow. Technicals are currently bearish (below key moving averages with negative MACD), while valuation is constrained by negative earnings and no dividend support. Positive corporate developments provide a modest offset.
To see Spark’s full report on IDYA stock, click here.
More about IDEAYA Biosciences
IDEAYA Biosciences, Inc. is a biotechnology company focused on developing precision medicine oncology therapies. The company operates in the biopharmaceutical sector, leveraging capital markets tools such as shelf registrations and at-the-market equity programs to finance its research and development and advance its pipeline of targeted cancer treatments.
Average Trading Volume: 1,204,236
Technical Sentiment Signal: Hold
Current Market Cap: $2.54B
Learn more about IDYA stock on TipRanks’ Stock Analysis page.